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Abstract
Purpose: To explore the effects of Icaritin on chronic myeloid leukemia (CML) cells and underlying mechanisms.
Method: CML cells were incubated with various concentration of Icaritin for 48 hours, the cell proliferation was analyzed by
MTT and the apoptosis was assessed with Annexin V and Hoechst 33258 staining. Cell hemoglobinization was determined.
Western blotting was used to evaluate the expressions of MAPK/ERK/JNK signal pathway and Jak-2/Phorpho-Stat3/Phorsph-
Akt network-related protein. NOD-SCID nude mice were applied to demonstrate the anti-leukemia effect of Icaritin in vivo.
Results: Icaritin potently inhibited proliferation of K562 cells (IC50 was 8 mM) and primary CML cells (IC50 was 13.4 mM for
CML-CP and 18 mM for CML-BC), induced CML cells apoptosis and promoted the erythroid differentiation of K562 cells with
time-dependent manner. Furthermore, Icaritin was able to suppress the growth of primary CD34+ leukemia cells (CML) and
Imatinib-resistant cells, and to induce apoptosis. In mouse leukemia model, Icaritin could prolong lifespan of NOD-SCID
nude mice inoculated with K562 cells as effective as Imatinib without suppression of bone marrow. Icaritin could up-
regulate phospho-JNK or phospho-C-Jun and down-regulate phospho-ERK, phospho-P-38, Jak-2, phospho-Stat3 and
phospho-Akt expression with dose- or time-dependent manner. Icaritin had no influence both on c-Abl and phospho-c-Abl
protein expression and mRNA levels of Bcr/Abl.
Conclusion: Icaritin from Chinese herb medicine may be a potential anti-CML agent with low adverse effect. The mechanism
of anti-leukemia for Icaritin is involved in the regulation of Bcr/Abl downstream signaling. Icaritin may be useful for an
alternative therapeutic choice of Imatinib-resistant forms of CML.
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Introduction
Chronic myeloid leukemia (CML) is a clonal myeloprolifer-
ative disease characterized by Philadelphia chromosome, which
generates Bcr/Abl fusion gene and P210 oncoprotein to
produce a constitutively active tyrosine kinase. The selective
tyrosine kinase inhibitor Imatinib can block this kinase activity
by occupying ATP binding site of Bcr/Abl and inhibit CML
cell growth effectively [1]. Based on clinical studies, including
early chronic phase (CP)[2,3], accelerated phase (AP)[4], and
myeloid blast crisis (BC)[5], Imatinib is considered as an
effective agents for the first-line therapy in newly diagnosed
CML-CP patient[6] and a conventional treatment option for
CML.
Unfortunately, resistance to Imatinib occurs frequently during
CML-AP and BC, resulting in remission intervals usually lasting
only 6 to 12 months. CML-BC is fundamentally different from
CML-CP in many aspects. The major features that occur during
CML progression are marked changes in growth, differentiation,
apoptosis, and cell adhesion [7,8]. On the other hand, blast crisis is
relatively resistant to tyrosine kinase inhibitor (TKI) therapy, even
the second-generation TKI [9]. Thus, novel therapeutic ap-
proaches that target signaling pathways other than Bcr/Abl are
urgently needed for treatment of CML.
Icaritin (Fig. 1A), a hydrolytic product of Icariin, is a constituent
of the traditional Chinese herbal medicine Epimedium. Icariin can
be metabolized into Icaritin by human intestinal bacteria in vitro,
while Icaritin may exert estrogen-like activities [10]. Previous
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activities, including cardiovascular function improvement, hor-
mone regulation, modulation of immunological function and anti-
tumor activity [11,12,13]. It has been reported that Icariin was
able to induce liver cancer cell line-SMMC-7721 cells apoptosis
[13], or to reverses the malignant phenotype of gastric carcinoma
cell line-SGC-7901 by suppressing the adhesion and migration of
cancer cells [14]. In hematological malignancy, it has been shown
that Icariin not only induced differentiation of promyelocytic
leukemia HL-60, but also lead to HL-60 cell apoptosis [15], which
involved a down-regulated Bcl-2 and c-myc expression [16].
However, the effects of Icaritin on other types of leukemia and the
underlying mechanisms remain elusive.
In this study, we investigated the effects of Icaritin on growth of
the Bcr/Abl-bearing K562 [17], primary CML cells (including
CD34+ cells), and imatinib-resistant cells, and found that Icaritin
inhibited growth and induced apoptosis and differentiation in
these cells, which provides strong rationales for potential clinical
application of Icaritin as a novel agent against CML.
Methods
Reagents and antibodies
Icaritin with a purity of up to 99.5% was provided by Dr. Kun
Meng (Shenogen Phama Group, Beijing, China). A stock solution
(20 mM/L) was prepared by dissolving Icaritin in DMSO (Sigma,
St. Louis, MO) and stored at 2200C.Imatinib-resistant cells were
obtained from Institute of zoology, Chinese Academy of Science,
Beijing. Human CD34 selection kit (EasySep) was purchased from
StemCell Technologies. Mitochondria isolation kit was purchased
from Thermo scientific Inc. SB203580 was from Calbiochem (San
Diego, CA). Antibodies for c-Abl, phospho-c-Abl, p-38, phospho-
Akt(Ser473),Apaf-1(R205), Jak-2,phospho-Stat3(Tyr705), phos-
pho-p38 were from Cell Signaling Technology (Beverly, MA).
C-Jun, phospho-c-Jun, ERK, phospho-ERK, JNK, phospho-JNK,
cytochrome c, caspase-3, caspae-9, Bcl-2, Bax, and b-actin
antibodies were from Santa Cruz biotechnology (Santa Cruz, CA).
Cell culture and cell proliferation assay
K562 cells were maintained in RPMI-1640 medium (Gibco)
containing 10% FBS at 37uC in a humidified atmosphere of 5%
CO2. Imatinib-resistant cells were maintained in the medium
containing 1 mM Imatinib mesylate(Novartis Pharmaceuticals)and
cultured in drug-free medium before all experimental procedures.
Primary CML cells were harvested from bone marrow samples of
CML patients and bone marrow mononuclear cells (BMMCs)
were isolated by Ficoll-Paque isolation solution. The CD34-
positive cells of bone marrow were isolated and purified by CD34
selection kit in 4 of patients with CML (1 case was resistant to
Imatinib therapy, 3 cases were in CML-BC). CML was diagnosed
according to clinical and laboratory criteria. All cases were
Philadelphia chromosome positive. Total 24 CML patients were
enrolled in the studies (14 CML-CP and 10 CML-BC) and 11
healthy individuals were used as controls. This study was
conducted according to the principles expressed in the Declaration
of Helsinki. The study was approved by the Institutional Review
Board of the Second Xiangya hospital, central South University.
All patients provided written informed consent for the collection of
samples and subsequent analysis. Fresh bone marrow mononu-
clear cells were isolated by Ficoll centrifugation and re-suspended
in PRMI-1640 medium supplemented with 10% FBS in an
incubator.
K562, Imatinib-resistant cells at exponential growth phase,
primary CML cells,primary normal bone marrow cells and
primary CD34+ cells from 4 CML-BC patients were treated with
Icaritin for 48 h in indicated concentrations and cell proliferation
was analyzed by MTT method [18]. For time courses analysis,
K562 cells were treated with 8 mM Icaritin for 2 h, 4 h, 8 h, 12 h
and 24 h. IC50 values were determined using a nonlinear
regression program calcusyn (Biosoft, Cambridge, UK). Cell
viability was determined with the trypan blue dye exclusion
method. Cell cycle analysis was performed as described [19].
Apoptosis assay
K562 or Imatinib-resistant cell (5610
4 cell/ml) were seeded in
6-well plates and treated with different concentrations of Icaritin as
indicated for 48 hours. The apoptotic morphology of K562 was
evaluated by Hoechst 33258 (KeyGen Biotech Co, Ltd) following
manufacturer’s protocol. Cells undergoing apoptosis were assessed
with an Annexin V (AV) apoptosis detection Kit I (Becton
Dickinson, USA). As an evaluation of apoptosis-related cyto-
chrome C change, Mitochondria and cytosol fraction for cultured
cells were isolated by special kit following the manufacturer’s
instruction. Cytochrome C protein in cytosol assay (western blot)
was finished.
Cytospin, Wright-Giemsa staining, benzidine staining and
flow-cytometry assay
Cells (5610
4 cells/ml) were spun onto a microscope slide and
stained with Wright-Giemsa solution. Cell hemoglobinization was
analyzed by benzidine staining as described [20]. In brief, 5610
5
cell/ml was mixed with 200 ml benzidine reagent dihydrochloride
(Sigma). The percentage of benzidine-positive cells (blue cells) was
determined by light microscopic examination. FACS Calibur
(Becton Dickinson, USA) was used to determine expression of
erythroid markers, such as glycophorin A (CD235a) and CD71
(Becton Dickinson, USA).
Real-time PCR assay
Total RNA was extracted from Icaritin-treated and untreated
K562 by using TRIzol reagent (Gibco, USA). Five micrograms of
RNA was reverse-transcribed into cDNA using Revert Aid TM
first-strand synthesis kit (Fermentas Inc, USA). Transcribed cDNA
was amplified and quantified with the real-time fluorescent
quantitative PCR using a Dynao SYBR Green qPCR kit
(Finnzyams, Finland). b-actin and BCR/ABL primers were
designed according to reference[21].
Western blot
Cells were homogenized on ice in lysis buffer (50 mM Tris-
HCL, PH 7.5, 150 mM NaCl, 1% NP-40, 0.25% Na-desoxycho-
late, 5 mM EDTA, 1 mM NaF, 25 mM Na3vo4, 0.1 mM PMSF
and 2 mg/mL Aprotinin). After determining the concentration,
equal amount of protein (,30 mg/well) was separated on 8% or
12% SDS-PAGE and transferred onto PVDF membranes. The
membranes were probed with various primary antibodies, HRP-
conjugated secondary antibodies, and visualized with enhanced
chemiluminescence (ECL) detection reagents (Amersham Phar-
macia Biotech).
In vivo tumor formation assays.
Female NOD-SCID nude mice (6 to 8 weeks old) from
Shanghai Experimental Animal Center Chinese Academy of
Sciences, Shanghai, China were used according to the animal
protocol. All animals were handled in strict accordance with good
animal practice as defined by the relevant national and local
animal welfare bodies, and all animal work was approved by the
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Central South University (permit number: SYXK(xiang) 2004-
0013). K562 at 2610
6 were injected into each mouse via tail vein.
After one week, the mice inoculated with K562 were randomized
into four groups (5 mice per group): (1) Untreated group as a
negative control; (2) Icaritin-treated group (4 mg/kg/day); (3)
Icaritin-treated group (8 mg/kg/day); (4) Imatinib-treated group
(150 mg/kg/day) as a positive control. The drugs were adminis-
trated into mice by intraperitoneal injection. Peripheral blood cells
were counted once a week. The percentages of leukemia cells after
labeled with FITC-conjugated anti-human CD45 antibody
(Becton Dickinson) were detected by flow cytometry. Survival of
mice was monitored from the first day of treatment until death.
The mice were euthanized when became moribund at the tenth
Figure 1. Icaritin inhibits K562 cells or primary chronic myeloid leukemic cells growth. A. Chemical structure of Icaritin. B. (a). Effects of
Icaritin on K562 cell proliferation (MTT assay). (b). Effects of Icaritin on fresh primary cells (BMMCs) growth from CML patients bone marrow (CML-CP:
14; CML-BC: 6) or fresh primary cells (BMMCs) growth from normal subjects (n=11) bone marrow (MTT assay). The values represent mean6SD of
triplicate cultures. (c). Effects of Icaritin on the growth inhibition of Imatinib-resistant cells line (C-line-R) or Imatinib-resistant primary cells from one
CML patient (CML-pR). (d). Proliferation-inhibition of Icaritin on CD34+ cells from 3 case of CML-BC patients.
doi:10.1371/journal.pone.0023720.g001
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spleen were collected, and pathological sections were prepared and
stained with hematoxylin-Eosin (HE).
Statistical analysis
The lifespan of mice was analyzed by Kaplan-Meier methods,
while the leukemia cell load, WBC numbers, CD45
+ cells and
spleen weight, were analyzed with one-way ANOVA and
independent sample t test. P values less than 0.05 were considered
statistically significant and were derived from 2-tailed statistical
test. All statistical treatment was performed using the software
SPSS 14.0 for windows (Chicago, IL).
Results
1. Icaritin inhibits proliferation of both K562, Imatinib-
resistant cells and primary CML cells
To determine the effects of Icaritin on growth of CML cells, we
treated cells with Icaritin at different concentrations and assessed
the cell growth by MTT assay. We found that Icaritin effectively
inhibited K562 proliferation (Fig. 1B-a) with rates of inhibition
31.5%, 58.2%, 77.1%, 85.6% and 89.8% for Icaritin concentra-
tion at 4, 8, 16, 32 and 64 mM, respectively. The IC50 value of
Icaritin was 8 mM. We also tested the effects of Icaritin on growth
of acute myeloid leukemia cell lines, including Raji, HL-60 and
kasumi-1. The results showed the IC50 values for inhibiting these
cells growth were 20 to 76 mM that were higher than that observed
in K562. We also observed that Icaritin inhibited proliferation of
primary CML cells from patients with CML-CP (14 cases) and
CML-BC (6 cases). Icaritin inhibited proliferation of these CML
cells in a dose-dependent manner (Fig. 1B-b). The IC50 values of
Icaritin on these cells were 13.4 mM (CML-CP) and 18 mM
(CML-BC), respectively. However, no significant effect was
observed for Icaritin-treated normal bone marrow cells (Fig 1B-
b).More importantly, we also found that Icaritin was able to
potently inhibit the growth of both Imatinib-resistant cells strain
and primary imatinib-resistant cells(CD34+) from one CML
patient (Fig 1B-c), indicating Icaritin, to a certain extent, may
play an role in reversing imatinib-resistance. In addition, we
confirmed that Icaritin showed similar effect in proliferation-
inhibition on CD34+ cells derived from CML-BC patients
(Fig 1B-d).
2. Icaritin induces K562 apoptosis.
To probe the mechanisms by which Icaritin inhibited cell
proliferation, we examined morphologic changes in Icaritin
treated cells. K562 exposed to different concentrations of Icaritin
for 48 h exhibited morphologic characteristics of apoptosis such as
condensation of nuclear, as revealed by Hoechst 33258 staining
(Fig. 2A) in an concentration dependent manner (Fig. 2B).
Externalized PS, a characteristic of early apoptosis, as revealed
with the annexin V staining, was significantly increased in Icaritin-
treated K562 compared to untreated cells (Fig. 2C).
Noticeably, primary bone marrow cells from five CML-BC
patients treated with Icaritin exhibited significant apoptosis in a
dose-dependent manner, as revealed with the annexin V assays
(Fig. 2D). Cell population in the sub-G1 phase was also increased
in Icaritin-treated K562 (Fig. 2E). Western blot was performed to
assess expression of Bcl-2, Bax and cytochrome C, and activation
of caspase-3, caspase-9 and Apaf-1. Icaritin significantly inhibited
Bcl-2 protein expression and up-regulated Bax protein expression
in K562 with a dose-dependent manner accompanied by the
cleavage activation of caspase-3 or caspase-9, and a down-
regulated expression of Apaf-1 (Fig. 2F). To further document that
the release of cytochrome C is from mitochondria, we prepared
the cytosolic fraction of K562 cells, and western blot was done.
The result showed that Icaritin could induce cytochrome C release
with dose-dependent manner (Fig.2F). These results suggest that
Icaritin induced cell apoptosis is involved in mitochondrial-
mediated caspase pathway. We then examined whether Icaritin
may induce CD34+ cells apoptosis in 4 cases with CML (1 for
Imatinib resistance; 3 for CML-BC) and Imatinib-resistant cells
line, As shown in Fig 2G, Icaritin could induce cells apoptosis
significantly both on CD34+ CML and Imatinib-resistant cells.
3. Icaritin induces K562 to differentiate toward the
erythroid lineage
Examination of Icaritin-treated K562 with light microscopy
revealed that the survived K562 exhibited morphological changes
such as reduction in cell volume indicating differentiation. Indeed,
Icaritin-treated K562 exhibited higher hemoglobin level com-
pared to untreated cells (Fig. 3A). The erythroid phenotype was
also confirmed with Benzidine staining (Fig. 3B, 3C). We also
analyzed the surface markers of erythroid with flow cytometry.
The results showed that glycophorin A (CD235a) and transferrin
receptor (CD71), erythroid specific antigens [22,23], to a certain
extent, had an increased expression in Icaritin treated K562 cells
(Fig. 3D), indicating that Icaritin induces erythroid differentiation
of K562.
The p38 has been shown to play a critical role in Icaritin-
mediated cardiomyocyte differentiation in vitro [24]. Western blot
results showed that Icaritin induced phosphorylation levels of p38
expression in K562 after treated for four days (Fig. 3E). The levels
of phosphorylated JNK were also induced by Icaritin treatment
(Fig. 3E), indicating that the p38 and JNK signal pathways were
involved in Icaritin-induced K562 cell differentiation.
To determine the functions of the p38 and JNK in Icaritin-
induced differentiation, K562 were treated with Icaritin alone or
together with a p38 inhibitor, SB203580. The erythroid
differentiation in these cells was assessed by benzidine staining
and MAPK-related proteins were evaluated on day 6 with
Western blotting. Figure 3F show that Icaritin-induced erythroid
differentiation was abolished by SB203580 treatment, while
SB203580 alone had no effect (Fig. 3F). Similarly, the increased
expression of P-P38 following Icaritin treatment was inhibited in
the presence of SB203580, while P-38 protein expression was not
influenced by SB203580 (Fig. 3F).
4. Icaritin has no effect on Bcr/Abl expression
Since Icaritin showed a similar effect on cell proliferation as
Imatinib, we assessed its influence on Bcr/Abl fusion protein of
K562. Our result showed that Icaritin at various concentrations
had no influence both on c-Abl protein or phosphorylated c-Abl
expression (by western blot) (Fig. 4A) and mRNA levels of Bcr/Abl
(by Real-time PCR) (Fig. 4B), indicating that Icaritin anti-leukemic
activity was not related to Bcr/Abl expression,and failed to
demonstrate any significant alteration of Bcr/Abl phosphorylation
level.
5. Icaritin inhibits MAPK/ERK/JNK downstream signaling
and diminishes Jak2/Stat3/Akt expression
To further characterize the mechanisms involved in the
proapoptotic action or proliferation- inhibiting of Icaritin, we
analyzed its effect on the main signaling pathways related to
proliferation or apoptosis regulation. After treated with Icaritin for
48 h, western blot was done. Our results demonstrated that
Icaritin might up-regulate phospho-JNK and phospho-C-Jun
Anti-Leukemia Activity of Icaritin on CML
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basal activation (Fig. 5A: e, f). Interestingly, although Icaritin failed
to affect ERK or P-38 expression (Fig. 5A: g, h), it could inhibit the
activation of phospho-ERK or phospho-P38 (Fig. 5A: c, d). Thus,
the main effect of Icaritin is to abolish P-ERK, P-P38 constitutive
activation in K562.The time-dependent effect of Icaritin on
above-mentioned proteins were also examined. As shown in
Fig. 3E-a, Icaritin treatment resulted in a significant increase in
phospho-JNK, and a down-regulated expression in phospho-ERK,
which were consistent with the changes of dose-dependent effect of
Icaritin.It has been reported that activation of Jak-2 is very
important for Bcr/Abl-mediated oncogenicity and may be a
potentially therapeutic target [25,26]. Akt kinase is also constitu-
tively active in the chronic phase of CML, blast crisis of CML, and
K562 cell line[27] and activation of Stat3 has been implicated in
survival signaling downstream of Bcr/Abl[28]. To assess the effects
of Icaritin on Jak2/Stat/Akt signal network, Western blot analysis
was completed. As shown in Fig. 5B, Icaritin both reduced Jak-2,
p-Stat3 and p-Akt expression at a dose- and time-dependent
manner, suggesting that Icaritin also disturbs Jak2/Stat3/Akt
signal pathway and facilitates the growth-arrest of leukemia cells.
These results, taken together, indicated that Icaritin induced CML
cell apoptosis was associated with MAPK/ERK/JNK signaling
regulation, and, at least in part, Jak2/Stat3/Akt signaling
interference may play a significant role in inhibiting cell
proliferation and survival of Bcr/Abl+ leukemia cells.
6. Icaritin inhibits growth of CML in vivo
To evaluate the anti-leukemia effect of Icaritin in vivo, NOD-
SCID mice receiving 2610
6 K562 cells inoculation were treated
with Icaritin. Mice treated with vehicle alone, splenomegaly was
very obvious and histological examination revealed extensive
infiltrations of leukemia cells in spleen, bone marrow and liver
(Fig. 6A), indicating K562 cells were able to invade these tissues.
Icaritin dramatically reduced these disseminated infiltrations as
effective as Imatinib (Fig. 6A). In Icaritin- and Imatinib-treated
Figure 2. Icaritin induces K562 cells or primary cells apoptosis. A. Morphological features for apoptosis in untreated and Icaritin-treated K562
cells were revealed by Hoechst 33258 staining. Condensed chromatin and apoptotic body could be found in Icaritin-treated K562 cells by
fluorescence microscope (Olympus, B650); 6400. B. Percentages of apoptotic cells in various concentration of Icaritin-treated K562 cells (Hoechst
33258 staining). The results represent mean6SD of triplicate experiments. C. Flow-cytometry analysis showed externalized PS, revealed by Annexin
staining, increased significantly in 32 mM Icaritin-treated K562 cells. D. Percentages of apoptotic cells in Icaritin-treated fresh primary cells from CML-
BP patients bone marrow (n=5) based on annexin V expression assays. Error bars represent SD of experiments. E. Cell cycle analysis showing sub-G1
content in Icaritin (32 mM)-treated cells (right panel) and control (left panel). F. Effects of Icaritin on caspase-9, caspase-3, Apaf-1, bax, bcl-2 and cyt-c
protein expression (western blot results). b-actin is used as loading control. G. Effects of Icaritin on apoptosis in Imatinib-resistant cells, CD34+cells
from one CML patient with Imatinib-resistance, and CD34+ cells from 3 cases with CML-BC (Annexin V analysis).
doi:10.1371/journal.pone.0023720.g002
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differentiation.K562 cells were treated with 8 mM Icaritin, and cultured for 6 days. Then cells were stained with Wright-Giemsa and photographed
(61000). B.C. Icaritin-treated K562 cells were stained with benzidine. Compared with control (Fig B: left panel), cells exhibited deep blue appearances
(Fig B: right panal) (61000); in 8 mM Icaritin concentration, the percentage of benzidine-positive cells was significantly higher than others
concentration (Figure C). D. The expression of erythroid differentiation specific antigens on 8 mM Icaritin-treated K562 cells-flow cytometry assay
results: upper panel: CD71 and control; bottom panel: glycophorin A (CD235) and control. E-a. Icaritin induced a prolonged activation of P-P38 in
K562 cells until 8 days. P-JNK activation was also been observed, but diminished after 6 days. P-ERK protein was down-regulated in Icaritin-treated
K562 cells (Western blotting results); E-b. Effects of Icaritin on MAPK pathways-time courses (0–24 hours). K562 cells were treated with 8 mM Icaritin in
the indicated time interval (hours), total celluar extracts were prepared and subjected to Western blot assay to evaluate levels of phosphorylated
forms of JNK, ERK and p38. b-actin was measured as control. The results showed Iaritin could up-regulate p-JNK level and inhibit p-ERK expression at
a time-dependent manner, while p-p38 change was not significant. F. Effects of inhibition of MAPK pathways on Icaritin-induced K562 cells
differentiation. (A). The K562 cells were treated with 8 mM Icaritin alone or together with 10 mM SB203580 from day 1 to day 6. Percentages of
benzidine staining positive cells were evaluated on day 6. **p,0.01 vs control. (B). For p-p38 protein expression analysis, samples were harvested on
day 6, and western blotting assay was performed. The result indicated that SB203580 could blunt Icaritin-induced P-38 phosphorylation.
doi:10.1371/journal.pone.0023720.g003
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of the group treated with vehicle (P,0.05)(Fig. 6 B.C). Both
directly counting and CD45 antigen assay showed that the
numbers of WBC in peripheral blood in vehicle treated mice were
significantly higher than those in Icaritin-treated mice (P,0.05)
(Fig. 6D.E). However, Icaritin caused neither bone marrow
suppression nor weight loss (Fig. 6F); indicating Icaritin has no
general cytotoxic effects.
We also found that Icaritin could prolong median survival time
of leukemia-bearing mice (39.5614.4 days for vehicle treated mice
versus 61.75610.5 days and 6760 days for mice treated with
Icaritin at 8 mg/kg/day and 4 mg/kg/day, respectively), that was
similar to the effect of Imatinib (Fig. 6G).
Discussion
In present study, we found Icaritin, a compound purified from
traditional herb medicine exhibited a potent anti-leukemia
activities towards established CML cell line-K562 and primary
bone marrow cells (including CD34+ cells) from CML patients.
Icaritin effectively inhibited K562 growth in vitro. At concentration
of 8 mM, Icaritin could lead to more than 50% of growth
inhibition of K562. More importantly, we also observed that
Icaritin exhibited strong efficacies on primary bone marrow cells
from CML-CP and CML-BC patients while had no effect on
growth and proliferation of normal bone marrow cells (Fig. 1B-b),
indicating Icaritin has low or no general cytotoxic effect on normal
hematopoiesis. Consistent with this, Icaritin showed potent effects
with low adverse reactions such as weight loss in vivo. We also
checked the effects of Icaritin on Imatinib-resistant cells line and
Imatinib-resistant primary cells from one CML patient, our results
suggested that Icaritin evidently inhibited the growth of both
Imatinib-resistant cells line and Imatinib-resistant primary cells.
Furthermore, we also confirmed that Icaritin could induce
Imatinib-resistant cells apoptosis. Although the results are
preliminary; this will be a new clue for searching an alternative
agent in overcoming Imatinib-resistance of Bcr/Abl+ cells.
Accumulating evidence indicated that many types of cancer,
including leukemia, originate from and are maintained by a small
of cancer stem/progenitor cells. These cancer stem/progenitor
cells are often resistant to most therapeutic strategies. In this study,
we enriched CML stem/progenitor cells from 3 patients with
CML-BC using CD34 selection kit and successfully isolated
CD34+ leukemia cells (the yield: 89.37%66.79%). Here, we
showed that Icaritin could effectively inhibit leukemic stem/
progenitor cells proliferation and induce apoptosis, and thus
suggesting that the effect of Icarintin on anti-leukemia activity may
preferentially target to leukemic stem/progenitor cells.
Figure 4. Effect of Icaritin on Bcr/Abl protein or mRNA expressions on K562 cells. A. K562 cells were incubated with different Icaritin
concentrations (0 mM, 4 mM, 8 mM, 16 mM, 32 mM, 64 mM) for 45 h, and then lyzed and separated by SDS-PAGE. Proteins were blotted on PVDF
membrane. c-Abl, p-c-abl and, Bcr/Abl protein levels were detected via immunoblot. b-actin was used as internal control. Results showed Icaritin had
no influence on Bcr/Abl, c-Abl and phosphorylated c-Abl protein expression. B. Quantitative real-time RT-PCR analysis for Bcr/Abl mRNA level. The
results indicated that compared with untreated K562 cells, Icaritin-treated K562 cells (both 8 mM and 32 mM) had no significant effect on the
expression of Bcr/Abl mRNA.
doi:10.1371/journal.pone.0023720.g004
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apoptotic pathways are involved in the activation of effectors
caspases (casp-3, casp-2 and casp-7). The extrinsic pathways is
initiated by binding death receptors, such as CD95/Fas, TNF or
TRAIL receptor to activate caspase-8 and caspese-10, which in
turn cleave and activate effectors caspases[29,30]. The involve-
ment of intrinsic apoptotic pathway is more often events especially
in cancer cells, which is characterized by the disruption of the
mitochondrial membrane and proteins release [31]. Our results
demonstrated that Icaritin was able to induce apoptosis, both in
K562 and primary CML cells. Icaritin inhibited Bcl-2 expression
and up-regulated Bax expression, which resulted in a lower ratio of
Bcl-2/Bax. We also found that cytochrome C levels were up-
regulated, caspase-9 and caspase-3 were cleavaged and activated,
Apaf-1 expression was down-regulated following Icaritin treat-
ment, indicating the mitochondrial permeability is changed. Based
on the observations, we suggested that mitochondrial-mediated
caspase cascade pathway plays a major role in Icaritin-induced
apoptosis.
K562 have been widely used as a model for leukemia
differentiation. It is known to be induced to differentiate along
either erythroid or megakaryocytic lineage [20]. In our experi-
ments, both morphologic and phenotypic analysis revealed that
after Icaritin treatment for 6 to 8 days, a significant number of
K562 exhibited erythroid-like features, including the change of cell
volume, increased Hb concentration, RBC benziding staining and
expression of erythroid specific markers, such as glycophorin-A
(CD235a) and transferring receptor (CD71). It has been shown
erythroid differentiation is a tightly regulated process that requires
specific transcription factors [32,33]. Accordingly, it has been
reported that hydroxyurea induced erythroid differentiation of
K562, which was associated with the activation of the p38 MAPK
pathway [34]. Davidson and Morange showed activation of the
p38 pathway was necessary for cardiomyogenesis of the P19
embryonic carcinoma cell line during early stages [35]. Recently,
Ding et al showed that Icaritin-induced cardiomyocyte differen-
tiation of murine embryonic stem cells was associated with
enhanced phosphorylation of p38[24]. Consistent with these
observations, we found that Icaritin significantly induced phos-
phorylation levels of p38 during K562 cell differentiation toward
erythroid lineage, which was blocked by p38 inhibitor SB203580.
We concluded Icaritin was able to induce CML cell differentiation
presumably through the p38 pathway.
The potent anti-leukemia efficacy of Icaritin in murine model
demonstrated that Icaritin was able to reduce the infiltration of
leukemia cells and alleviate the load of leukemia cells in peripheral
blood and spleen; effects were similar to those of Imatinib. Survival
study also showed that Icaritin was able to significantly prolong the
lifespan of mice loaded with leukemia. We found that Icaritin
failed to influence Bcr/Abl expression in K562. However, whether
Icaritin has influence on the downstream signal pathways of Bcr/
Abl need to be further proven.
The anti-apoptotic activity of Bcr/Abl contributes greatly to the
development of CML. Bcr/Abl may function either by enhancing
Figure 5. Effects of Icaritin on MAPK/ERK/JNK signaling pathways and Jak2/Stat3/Akt axes. A. Icaritin could up-regulate phospho-JNK, or
phospho-C-Jun (Fig.5A- a, b.), and down-regulate phosphor-ERK, phospho-P-38 expressions (Fig.5A-c, d) with dose-dependent manner. While JNK,
C-jun, ERK, p38 (Fig.5A-e, f, g, h) expressions were not influenced by Icaritin. Normalization was performed using b-actin (Fig.5A-i). B. Icaritin
diminishes constitutive activation of JAK-2, p-Stat3 and p-Akt in K562 cells at time- or dose-dependent manner. K562 cells were treated with 8 mM
Icaritin for 1-24 hours (left panel), or with different concentrations of Icaritin (0–64 mM) (right panel). After which the cells were lysed and subjected to
Western blot analysis to monitor expression of JAK-2, phosphorylated Stat3 and Akt.
doi:10.1371/journal.pone.0023720.g005
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protecting these progenitor cells from apoptosis [36,37]. Accumu-
lating evidence shows that the constitutive tyrosine kinase activity
of Bcr-Abl is essential for its leukemogenic activity [38]. Bcr-Abl-
mediated signal transduction pathways could interfere with
various cellular physiological processes, including cells prolifera-
tion, adhesion, and apoptosis [39,40]. These processes are thought
to involve in intracellular signaling pathways, such as MEK/ERK,
JNK/SAPK and p38MAPK [41,42,43]. It has been shown that
the STAT family of transcription factors plays important role in
transformation and antiapoptotic signaling stemming from
constitutive activation of Bcr/Abl kinase [44,45]. As a driving
force for CML, the activated tyrosine kinase of Bcr/Abl is able to
stimulate the Janus kinase (Jak) 2 pathway [25]. Furthermore,
PI3K/Akt pathway has emerged as one of the essential signaling
mechanisms in Abl leukemogenesis as its downstream effectors are
responsible for propagating the signals to promote myeloid and
lymphoid transformation[46]. To assess whether the effect of
Icaritin on anti-leukemia is involves in the inactivation of Jak-2/
Stat-3/Akt axes, western blot was used for evaluating the
expression of Jak-2, p-Stat-3 and p-Akt protein. It is noteworthy
that the exposure of K562 cells to Icaritin resulted in diminished
phospho-p38 or phospho-ERK expression, and induced activation
of phospho-JNK or phospho-c-Jun, which contributes apparently
to the apoptosis of Bcr/Abl+ cells. Significantly, Icaritin can
obviously down-regulate the expression of Jak-2, phospho-Stat3
and phospho-Akt protein at a dose- and time-dependent manner,
suggesting that the interruption of Jak-2/Stat-3/Akt signal
network by Icaritin contributes to the growth-inhibition and
diminished survival of K562 cells. Collectively, these observations
suggest that transcriptional repression by Icaritin lowers the
proliferation potential for Icaritin-mediated growth-inhibition of
Bcr/Abl+ leukemia cells. On the other hand, the possibility that
the action of Icaritin as an apoptosis-activator contribute to a
diminished apoptotic threshold cannot be completely excluded.
However, exact molecular mechanisms on anti-leukemia activity
of Icaritin still need to be elucidated.
In conclusion, we have documented for the first time the anti-
CML effects of Icaritin in vitro and in vivo. Our findings have shown
that Icaritin was able to inhibit CML cell growth, and induce
apoptosis and differentiation. The underlying mechanisms of
Icaritin anti-CML activity are involved in the inhibition of
MAPK/ERK/JNK signals and down-regulated kinase activity of
Jak-2/Stat-3/Akt signal network. Further investigation of this
novel anti-CML agent may offer insights into the pathogenetic
mechanisms of CML and provide a new approach for CML
treatment and a reversal to Imatinib-resistance.
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